Business Segments · General And Administrative Expense
Business Segments — General And Administrative Expense
Polaryx Therapeutics, Inc. Business Segments — General And Administrative Expense increased by 254.6% to $812.00K in Q1 2026 compared to the prior quarter. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
How to read this metric
Rising expenses may signal scaling operations or increased regulatory compliance needs, whereas declining expenses suggest improved operational leverage.
Detailed definition
This metric captures the overhead and administrative costs directly or indirectly allocated to the lysosomal storage dis...
Peer comparison
Similar to SG&A allocations in other pharmaceutical companies, this metric is used to benchmark the cost of maintaining a specific therapeutic franchise.
Metric ID:
plyx_segment_lysosomal_storage_disorders_general_and_administrative_expenseHistorical Data
2 periods
| Q1 '25 | Q1 '26 | |
|---|---|---|
| Value | $229.00K | $812.00K |
| QoQ Change | — | +254.6% |
| YoY Change | — | +254.6% |
Range$229.00K – $812.00K
Avg YoY Growth+254.6%
Median YoY Growth+254.6%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Polaryx Therapeutics, Inc. 's business segments — general and administrative expense?
- Polaryx Therapeutics, Inc. (PLYX) reported business segments — general and administrative expense of $812.00K in Q1 2026.
- What does business segments — general and administrative expense mean?
- The administrative and overhead costs required to support the lysosomal storage disorders business segment.